For people living with both type 2 diabetes and atrial fibrillation, choosing the right glucose-lowering drug may affect far more than a blood sugar reading.
A new U.S. study found that patients who started GLP-1 drugs had a 36 percent lower risk of dying within one year than closely matched patients who started SGLT-2 inhibitors.
The GLP-1 group also had fewer hospital stays, major cardiovascular events, and procedures used to control atrial fibrillation. Still, this is not a simple instruction to swap medications, because SGLT-2 drugs remain especially important for many people with heart failure or kidney disease.
A clear gap after one year
The researchers used records from 108 U.S. health systems and compared 18,035 new GLP-1 users with the same number of new SGLT-2 users. Md Mohaimenul Islam, who called the two diagnoses together “a punishing combination,” led the analysis with Arinze Nkemdirim Okere at the University at Buffalo.
After one year, GLP-1 users had a 12 percent lower risk of hospitalization and a 22 percent lower risk of heart attack, stroke, or cardiovascular death.
They were also about 20 percent less likely to undergo cardioversion or ablation, procedures doctors use to restore or control an abnormal heart rhythm. The findings were similar across age and weight groups.
The 36 percent number describes a relative difference between the two matched groups. It does not mean that 36 out of every 100 patients were prevented from dying, and the available summary did not provide the absolute death rates needed to calculate that difference.
How these diabetes drugs work
GLP-1 receptor agonists copy some of the work of a natural gut hormone released after eating. They help the pancreas release insulin when blood sugar is elevated, reduce glucagon that would otherwise push glucose higher, and often curb appetite.
Well-known examples include semaglutide products such as Ozempic and Wegovy.
SGLT-2 inhibitors take a different route. They block the kidneys from pulling as much glucose back into the bloodstream, so more sugar leaves the body in urine. Jardiance and Farxiga are examples, and their benefits extend beyond the glucose number on a lab report.
Could weight loss and lower metabolic strain help explain the GLP-1 advantage? Possibly, especially because obesity can worsen both diabetes and Afib, but this study did not test the biological reason for the difference. It measured what happened to patients, not exactly why it happened.
Why Afib changes the equation
Atrial fibrillation is an irregular rhythm in the heart’s upper chambers. Blood can pool instead of moving smoothly, which can allow clots to form and travel to the brain. That is why Afib is closely tied to stroke and can also contribute to heart failure and other serious complications.
Type 2 diabetes adds another layer of strain to the heart, blood vessels, and kidneys. Obesity and aging are common threads, while excess body fat can encourage inflammation, metabolic stress, and physical changes in the atria.
In everyday terms, two already difficult conditions can keep pushing each other in the wrong direction.
A separate 2025 analysis of U.S. death records counted 419,036 deaths among adults age 25 and older who had diabetes and Afib between 1999 and 2020. The age-adjusted mortality rate rose sharply over that period, showing why researchers increasingly view this combination as a distinct clinical challenge.
SGLT-2 drugs still have a major role
The headline number favors GLP-1 drugs, but the medical decision is not winner-takes-all. SGLT-2 inhibitors have strong evidence for slowing chronic kidney disease and reducing heart failure risk, and current diabetes standards continue to recommend them for many patients with those conditions.
That means a patient with established heart failure or progressive kidney disease may still be better served by an SGLT-2 drug. For someone with diabetes and Afib who does not yet have those complications, the new findings give clinicians another piece of evidence to weigh.
The full medical picture matters more than any single percentage.
No one should stop or change a prescription based on this study alone. The decision should account for heart failure, kidney disease, obesity, Afib, and the patient’s broader clinical history, with guidance from a health professional.
What the study cannot prove
This was an observational study built from electronic patient records, not a randomized clinical trial. The investigators matched the two groups on many known characteristics, but unrecorded differences and prescribing decisions could still have affected the results.
An association, even a strong one, does not prove that the drug itself caused every benefit.
The follow-up also lasted only one year. That is long enough to spot meaningful differences in deaths and hospital care, but not enough to settle how the drugs compare over many years as heart failure or kidney disease progresses. Further research, ideally including randomized trials and longer follow-up, is needed.
For now, the most useful takeaway is precision rather than a blanket switch. The findings suggest GLP-1 drugs may deserve extra consideration for the growing group with type 2 diabetes and established Afib, while SGLT-2 inhibitors remain central when heart failure or kidney disease leads the clinical picture.
The official study was published in Diabetes Research and Clinical Practice.
